Press release
Homozygous Familial Hypercholesterolemia Market Landscape 2025: Key Drivers, Restraints, and Growth Opportunities | AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd.
Homozygous Familial Hypercholesterolemia Market
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic disorder that severely elevates low-density lipoprotein (LDL) cholesterol levels. It occurs when a person inherits defective LDL receptor genes from both parents. This leads to inefficient clearance of cholesterol from the bloodstream, causing early-onset cardiovascular disease. Symptoms may include xanthomas, corneal arcus, and arterial plaque buildup in childhood. Without aggressive treatment, such as lipid-lowering drugs or LDL apheresis, premature heart disease is common. Early diagnosis and lifelong management are crucial to prevent complications.
📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Homozygous Familial Hypercholesterolemia Market Landscape:- https://datamintelligence.com/download-sample/homozygous-familial-hypercholesterolemia-market?Ranjith
☛ Homozygous Familial Hypercholesterolemia Market Recent Developments 2025:
United States: Recent Industry Developments
✅ In July 2025, Regeneron Pharmaceuticals announced positive Phase 3 results for Evinacumab (Evkeeza) in pediatric patients with Homozygous Familial Hypercholesterolemia (HoFH). The therapy showed a significant reduction in LDL-C levels, expanding its potential use across age groups.
✅ In June 2025, Amgen Inc. reported promising long-term data on Repatha (evolocumab) demonstrating sustained LDL-C lowering and cardiovascular risk reduction in HoFH patients when combined with standard lipid-lowering therapies.
✅ In May 2025, Verve Therapeutics advanced its base-editing therapy (VERVE-101) targeting the PCSK9 gene into early clinical trials for HoFH, marking a major milestone in gene-editing-based cardiovascular therapeutics.
Japan: Recent Industry Developments
✅ In July 2025, Kowa Pharmaceutical initiated a clinical collaboration to evaluate a novel siRNA-based therapy targeting ANGPTL3 for severe hypercholesterolemia, aiming to improve lipid control in HoFH patients resistant to current therapies.
✅ In June 2025, Daiichi Sankyo announced early-stage research into lipid nanoparticle (LNP)-delivered RNA therapeutics for genetic cholesterol disorders, including HoFH.
✅ In May 2025, Takeda Pharmaceutical partnered with academic institutions to develop precision diagnostic tools for early identification of familial hypercholesterolemia using genomic sequencing technologies.
☛ Homozygous Familial Hypercholesterolemia Market Competitive Landscape:
AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd., Accord Healthcare, Changzhou Pharmaceutical Factory, Regeneron Pharmaceuticals, Inc., Amryt Pharma plc, Amgen Inc., Organon, Global Inc., CMP Pharma.
Research Methodology
We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.
📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/homozygous-familial-hypercholesterolemia-market?Ranjith
☛ Segments Covered in the Homozygous Familial Hypercholesterolemia Market:
By Drug Class: Statins, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, MTP Inhibitors, ANGPTL3 Inhibitors.
By Route of Administration: Oral, Parenteral, Nasal.
By Technology: CRISPR-Cas9, RNA Interference, Nanoparticle-Based Therapies.
By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies.
☛ This Report Includes:
✔ Comprehensive go-to-market strategies with actionable insights.
✔ Unbiased evaluation of overall market performance.
✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.
✔ Tailored regional and country-level reports with detailed localized analysis available on request.
✔ Identification of niche segments and high-growth regions presenting strong opportunities.
✔ Accurate regional forecasts using both top-down and bottom-up approaches.
📌 Get Corporate Access to Live Homozygous Familial Hypercholesterolemia Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=homozygous-familial-hypercholesterolemia-market?Ranjith
☛ Regional Analysis for Homozygous Familial Hypercholesterolemia Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription
☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Homozygous Familial Hypercholesterolemia Market Landscape 2025: Key Drivers, Restraints, and Growth Opportunities | AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd. here
News-ID: 4222006 • Views: …
More Releases from DataM Intelligence 4market Research LLP
Lumbar Degenerative Disc Disease Market Analysis, Size, Share, and Growth Foreca …
Global Lumbar Degenerative Disc Disease Market reached US$ 12.1 billion in 2022 and is expected to reach US$ 21.3 billion by 2031, growing with a CAGR of 7.4% during the forecast period 2024-2031.
Lumbar Degenerative Disc Disease (DDD) is a condition characterized by the gradual deterioration of the intervertebral discs in the lower back. It commonly results from aging, repetitive strain, or injury. As the discs lose hydration and elasticity, they…
Underwater Drone Market Growth Driven by Defense, Offshore Energy, and Marine Re …
The Underwater Drone Market was valued at US$ 3.42 billion in 2023, increased to US$ 3.94 billion in 2024, and is projected to reach US$ 16.06 billion by 2033, growing at a CAGR of 16.9% during the forecast period 2025-2033.
The market focuses on the development and deployment of unmanned underwater vehicles (UUVs) for applications in marine research, defense, oil & gas inspection, and environmental monitoring. Rising demand for deep-sea exploration,…
Railway Connector Market Poised for Steady Growth Driven by Electrification, Sma …
The Railway Connector Market was valued at US$ 0.99 billion in 2023, increased to US$ 1.03 billion in 2024, and is projected to reach US$ 1.72 billion by 2033, growing at a CAGR of 5.88% during the forecast period (2025-2033).
The market focuses on providing reliable and durable electrical connectors for rail infrastructure, rolling stock, signaling systems, and communication networks. Growing investments in high-speed rail projects, railway electrification, and the adoption…
U.S. Waste Management Market to Reach USD 484.8 Million by 2030, Driven by Techn …
The U.S. waste management market, valued at USD 342.7 million in 2023, is projected by DataM Intelligence to reach USD 484.8 million by 2030, with a CAGR of 5.2% from 2024 to 2030. Growth is propelled by rising waste volumes due to population expansion, globalization, and urbanization, alongside increased environmental awareness and adoption of sustainable waste disposal practices. Technological innovation, shifting consumer lifestyles, and policy-driven recycling initiatives are accelerating adoption…
More Releases for Homozygous
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Homozygous Familial Hypercholesterolemia (HoFH) Market Massive Growth opportunit …
Introduction
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic lipid disorder characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels from birth, often exceeding 500 mg/dL. Caused by mutations in both alleles of the LDLR, APOB, or PCSK9 genes, HoFH leads to early-onset atherosclerosis, cardiovascular disease, and premature mortality if untreated.
Historically, management relied on lipid-lowering agents, LDL apheresis, and lifestyle modifications. However, the last decade has witnessed a paradigm shift with…
Homozygous Familial Hypercholesterolemia Market 2025 | Market Growth, Genetic Sc …
Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2030 growing with a CAGR of 2.5% during the forecast period 2023-2030, according to DataM Intelligence research report, as per DataM intelligence research report.
Homozygous Familial Hypercholesterolemia Market: Recent Industry Developments
United States
✅ Regeneron announced the FDA extension of Evkeeza use to children aged 5-11 with HoFH, making it the first ANGPTL3 inhibitor…
New Syndrome: seemingly unrelated symptoms have a common cause in patients with …
The International H63D Mutation Research Consortium www.h63d-syndrome.org has announced the discovery of "Typ-2 H63D Syndrome", a genetic disease caused by a homozygous mutation of the HFE gene H63D. The research work, which spanned 12 years, uncovered that the mutation is responsible for a wide range of symptoms due to micro-inflammations, which can be challenging to diagnose without the proper knowledge and testing.
While classic Typ-1 H63D Syndrome is a rare disorder…
Latest Homozygous Familial Hypercholesterolemia Treatment Market Research | Comp …
Homozygous Familial Hypercholesterolemia Treatment Market
Market Strides has added a new report titled, “Global Homozygous Familial Hypercholesterolemia Treatment Market Professional Report 2027” to its vast repository of research reports. This is a comprehensive report focused on the current and future prospects of the Global Homozygous Familial Hypercholesterolemia Treatment Market. The report also mentions the impact of the coronavirus pandemic on the market. Furthermore, the study includes the steps the leading industry…
Homozygous Familial Hypercholesterolemia Treatment Market Size - Technological A …
Up Market Research (UMR) has published a latest market research report on Global Homozygous Familial Hypercholesterolemia Treatment Market. The global report is prepared in collaboration with the leading industry experts and dedicated research analyst team to provide an enterprise with in-depth market insights and help them to take crucial business decisions. This report covers current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.
The…
